Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Naunyn Schmiedebergs Arch Pharmacol
2011 Feb 01;3832:119-39. doi: 10.1007/s00210-010-0583-9.
Show Gene links
Show Anatomy links
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Staudacher I
,
Wang L
,
Wan X
,
Obers S
,
Wenzel W
,
Tristram F
,
Koschny R
,
Staudacher K
,
Kisselbach J
,
Koelsch P
,
Schweizer PA
,
Katus HA
,
Ficker E
,
Thomas D
.
???displayArticle.abstract???
Cardiac side effects of antidepressant drugs are well recognized. Adverse effects precipitated by the tricyclic drug desipramine include prolonged QT intervals, torsade de pointes tachycardia, heart failure, and sudden cardiac death. QT prolongation has been primarily attributed to acute blockade of hERG/I(Kr) currents. This study was designed to provide a more complete picture of cellular effects associated with desipramine. hERG channels were expressed in Xenopus laevis oocytes and human embryonic kidney (HEK 293) cells, and potassium currents were recorded using patch clamp and two-electrode voltage clamp electrophysiology. Ventricular action potentials were recorded from guinea pig cardiomyocytes. Protein trafficking and cell viability were evaluated in HEK 293 cells and in HL-1 mouse cardiomyocytes by immunocytochemistry, Western blot analysis, or colorimetric MTT assay, respectively. We found that desipramine reduced hERG currents by binding to a receptor site inside the channel pore. hERG protein surface expression was reduced after short-term treatment, revealing a previously unrecognized mechanism. When long-term effects were studied, forward trafficking was impaired and hERG currents were decreased. Action potential duration was prolonged upon acute and chronic desipramine exposure. Finally, desipramine triggered apoptosis in cells expressing hERG channels. Desipramine exerts at least four different cellular effects: (1) direct hERG channel block, (2) acute reduction of hERG surface expression, (3) chronic disruption of hERG trafficking, and (4) induction of apoptosis. These data highlight the complexity of hERG-associated drug effects.
Alderton,
Tricyclic medication in children and the QT interval: case report and discussion.
1995, Pubmed
Alderton,
Tricyclic medication in children and the QT interval: case report and discussion.
1995,
Pubmed
Bertschy,
Desipramine dose prediction based on 24-hour single-dose levels: feasibility and validity.
1989,
Pubmed
Bianchi,
herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells?
1998,
Pubmed
,
Xenbase
Biederman,
A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings.
1989,
Pubmed
Blair,
Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology.
2004,
Pubmed
Brøsen,
Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.
1986,
Pubmed
Burckhardt,
Cardiovascular effects of tricyclic and tetracyclic antidepressants.
1978,
Pubmed
Casazza,
[Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case].
1986,
Pubmed
Cherubini,
HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium.
2000,
Pubmed
Claycomb,
HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.
1998,
Pubmed
Coccaro,
Second generation antidepressants: a comparative review.
1985,
Pubmed
Cordes,
Pentamidine reduces hERG expression to prolong the QT interval.
2005,
Pubmed
Crociani,
Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells.
2003,
Pubmed
Daugherty,
The role of catecholamines in the production of ischaemia-induced ventricular arrhythmias in the rat in vivo and in vitro.
1986,
Pubmed
Dhein,
An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
2008,
Pubmed
Dietrich,
Cardiac toxicity in an adolescent following chronic lithium and imipramine therapy.
1993,
Pubmed
Du,
Protection of neuronal uptake-1 inhibitors in ischemic and anoxic hearts by norepinephrine-dependent and -independent mechanisms.
1998,
Pubmed
Eisenberg,
Solvation energy in protein folding and binding.
,
Pubmed
Ekins,
Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.
2002,
Pubmed
Farid,
New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.
2006,
Pubmed
Fenster,
Antiarrhythmic efficacy of desipramine.
1989,
Pubmed
Ficker,
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
2004,
Pubmed
Ficker,
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.
2003,
Pubmed
Fischer,
Accuracy of binding mode prediction with a cascadic stochastic tunneling method.
2007,
Pubmed
Glassman,
The use of imipramine in depressed patients with congestive heart failure.
1983,
Pubmed
Gong,
HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells.
2010,
Pubmed
Gong,
Role of glycosylation in cell surface expression and stability of HERG potassium channels.
2002,
Pubmed
Guo,
Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines.
2009,
Pubmed
Guo,
Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
2007,
Pubmed
Hondeghem,
QT prolongation is an unreliable predictor of ventricular arrhythmia.
2008,
Pubmed
Hondeghem,
Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.
2008,
Pubmed
Hong,
Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine.
2010,
Pubmed
,
Xenbase
Jiang,
X-ray structure of a voltage-dependent K+ channel.
2003,
Pubmed
Kiehn,
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
1999,
Pubmed
,
Xenbase
Kokh,
Flexible side chain models improve enrichment rates in in silico screening.
2008,
Pubmed
Kuryshev,
Pentamidine-induced long QT syndrome and block of hERG trafficking.
2005,
Pubmed
Kurz,
Nonexocytotic noradrenaline release and ventricular fibrillation in ischemic rat hearts.
1995,
Pubmed
Lenkey,
The mechanism of activity-dependent sodium channel inhibition by the antidepressants fluoxetine and desipramine.
2006,
Pubmed
Leonard,
Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents.
1995,
Pubmed
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Morita,
The QT syndromes: long and short.
2008,
Pubmed
Mosmann,
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
1983,
Pubmed
NULL,
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
2000,
Pubmed
Obers,
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
2010,
Pubmed
,
Xenbase
Petrecca,
N-linked glycosylation sites determine HERG channel surface membrane expression.
1999,
Pubmed
Rajamani,
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
2006,
Pubmed
Redfern,
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
2003,
Pubmed
Robertson,
Endocytic control of ion channel density as a target for cardiovascular disease.
2009,
Pubmed
Roden,
Repolarization reserve: a moving target.
2008,
Pubmed
Sanguinetti,
Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
1990,
Pubmed
Sanguinetti,
hERG potassium channels and cardiac arrhythmia.
2006,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Satoh,
Role of poly(ADP-ribose) formation in DNA repair.
1992,
Pubmed
Sawyer,
A case of severe acute desipramine overdose.
1984,
Pubmed
Schumacher,
Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.
2009,
Pubmed
Shah,
Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
2005,
Pubmed
Sindrup,
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
1990,
Pubmed
Smith,
Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells.
2002,
Pubmed
Staudacher,
hERG: protein trafficking and potential for therapy and drug side effects.
2010,
Pubmed
Swanson,
Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms.
1997,
Pubmed
Takemasa,
Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
2008,
Pubmed
Thomas,
Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, I(Kr), and the underlying hERG ion channel.
2004,
Pubmed
Thomas,
Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.
1999,
Pubmed
,
Xenbase
Thomas,
High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
2001,
Pubmed
,
Xenbase
Thomas,
Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing.
2003,
Pubmed
Thomas,
Doxazosin induces apoptosis of cells expressing hERG K+ channels.
2008,
Pubmed
Thomas,
The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
2006,
Pubmed
Thomas,
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
2004,
Pubmed
,
Xenbase
van der Heyden,
Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?
2008,
Pubmed
Varley,
Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications.
2001,
Pubmed
Viskin,
Long QT syndromes and torsade de pointes.
1999,
Pubmed
Wang,
HERG K+ channel, a regulator of tumor cell apoptosis and proliferation.
2002,
Pubmed
Wang,
Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
2007,
Pubmed
Wang,
Intracellular potassium stabilizes human ether-à-go-go-related gene channels for export from endoplasmic reticulum.
2009,
Pubmed
Warmke,
A family of potassium channel genes related to eag in Drosophila and mammals.
1994,
Pubmed
Waslick,
Cardiovascular effects of desipramine in children and adults during exercise testing.
1999,
Pubmed
Wible,
HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
2005,
Pubmed
Witchel,
Psychotropic drugs, cardiac arrhythmia, and sudden death.
2003,
Pubmed
Zahradník,
Inhibition of the cardiac L-type calcium channel current by antidepressant drugs.
2008,
Pubmed
Zhou,
HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects.
1998,
Pubmed
Zhou,
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.
1998,
Pubmed
